Top Stories
Latest
|
Exclusives
See more- Tech Traders Are Speed-Dating Volatility And Palantir Is The Perfect Case Study
- EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients
- EXCLUSIVE: DeFi Development Makes Record Solana Purchase, Surpasses $100 Million In Treasury Holdings
- Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
- EXCLUSIVE: Inuvo Clocks 57% Topline Growth, Margin Shrinks Due To Product Mix
- EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program
- EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million
- EXCLUSIVE: Aduro's Deal With Cleanfarms Targets Farm Plastic Recycling Revolution And Scalable Sustainability
- They Turned Fruit Bouquets Into A $500 Million-A-Year Business—Now They're Selling THC. Here's Why
- EXCLUSIVE: Trump's Approval Rating Drops In Reader Survey After 100 Days, Could Stock Market Be To Blame?
- EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program
- EXCLUSIVE: Nobody Believed A 100% International ETF Could Beat 1,000+ Rivals, Until This CEO Proved Them Wrong — His Mantra? 'Precision Over Breadth'
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
